Epitope Binding
Epitope Binding - Related Videos
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
0 Views •
Cited by 21 •
2014
Biochemical assays with recombinant human MHC II molecules can provide rapid, quantitative insights into immunogenic epitope identification, deletion, or design. Here, a peptide-MHC II binding assay scaled to 384-well plates is described. This cost effective format should prove useful in the fields of protein deimmunization and vaccine design and development.
13:58
Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells
0 Views •
Cited by 28 •
2012
This protocol describes the use of peptide:MHC tetramers and magnetic microbeads to isolate low frequency populations of epitope-specific T cells and analyze them by flow cytometry. This method enables the direct study of endogenous T cell populations of interest from in vivo experimental systems.
08:09
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
0 Views •
Cited by 15 •
2017
Here, the authors present a simple and efficient protocol to define a linear antigenic epitope using a purified monoclonal antibody and peptide scanning through dot-blot hybridization. The identified epitope can then be used in therapeutic and diagnostic applications.
02:18
The Equilibrium Binding Constant and Binding Strength
0 Views •
2020
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium: where P and L are the unbound protein and ligand, respectively, and PL is the protein-ligand complex. As the amount of bound ligand is also related to the rate of ligand binding, experiments can also determine Kb by examining the rates of protein-ligand association (kon) and dissociation (koff) using the following ratio: Thus,...
13:41
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
0 Views •
Cited by 9 •
2012
Characterizing T-cell epitopes of pathogens that cause localized infections such as human papillomavirus is a challenge because of limited number of T cells in circulation. A method is described in which rare T cells were isolated and were characterized starting with a very small number of cells.
FAQs
Selectivity depends on the fit between an epitope and the receptor’s or antibody’s paratope, not on a single chemical contact alone. Complementary shape and chemical properties allow multiple noncovalent interactions, including hydrogen bonds, electrostatic forces, and hydrophobic contacts. Together, these contacts support sufficiently specific recognition for downstream immune effects such as neutralization or cellular activation.
Accessibility is a decisive condition for productive recognition. Although an antigen may contain many molecular regions, binding depends on whether the relevant epitope is available for contact with the paratope. This makes the physical presentation of an antigen important when interpreting immune recognition, because an inaccessible region cannot readily participate in the interaction described by the binding model.
Epitope binding helps distinguish specificity from cross-reactivity. A highly selective interaction favors recognition of one molecular target, whereas cross-reactivity becomes relevant when recognition is not restricted to a single target. Examining these outcomes allows researchers to study how complementary molecular features govern immune discrimination and why an antibody or receptor may respond to related antigenic structures.
In antibody-based diagnostics, epitope binding provides the recognition event that connects an antibody to a molecular target. The interaction’s selectivity can therefore support diagnostic applications intended to distinguish relevant antigens from other molecules. Studying which epitopes are recognized also helps interpret diagnostic performance in terms of immune specificity rather than treating antibody attachment as a nonspecific process.
Vaccine design uses epitope-binding information to examine which antigenic regions can engage immune receptors or antibodies. Because the interaction reflects both molecular accessibility and complementarity, this perspective connects candidate antigen structure with immune recognition. The resulting analysis can support investigation of specificity and potential immune responses when researchers evaluate vaccine-related targets.
Therapeutic development and basic biology both benefit from analyzing which epitopes are recognized. In therapeutic contexts, binding may be examined in relation to outcomes such as neutralization or cellular activation. In research, the same framework helps investigate immune recognition, receptor or antibody specificity, and cross-reactivity, linking molecular interaction to biological response.